Poly(N‐vinyl‐pyrrolidone)‐block‐poly(D,L‐lactide) as polymeric emulsifier for the preparation of biodegradable nanoparticles

Gaucher, Geneviève; Poreba, Monika; Ravenelle, François; Leroux, Jean‐Christophe

doi:10.1002/jps.20833

Cited by 34 publications

(26 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its low water solubility does pose a formulation challenge. It has been reported that PCL-PEG-PAMAM and stPCL-PEG 32 polymeric micelles could achieve etoposide loading concentrations at 0.95 and 0.50 mg/mL, respectively [36, 37]. We observed P-1-4 micelles could entrap etoposide much more efficiently, reaching a drug concentration of 4.3 mg/mL in water.…”

Section: Resultsmentioning

confidence: 50%

A novel size-tunable nanocarrier system for targeted anticancer drug delivery

Xiao

Luo

et al. 2010

Journal of Controlled Release

116

View full text Add to dashboard Cite

We have developed a nanocarrier drug-delivery system based on micelles formed by a new class of well-defined linear PEGylated two-arm oligomer of cholic acids in aqueous solution. By varying the length of the linear PEG chains and the configuration of cholic acid oligomer, one can easily finetune the physicochemical properties of the amphiphilic polymers and the resulting micelles. These include particle size, critical micelle concentration, and drug loading capacity. High level of hydrophobic anticancer drugs such as PTX, etoposide and SN-38 can be readily loaded into such nanocarriers. The loading capacity of the nanocarrier for PTX (PTX) is extremely high (12.0 mg/ mL), which is equivalent to 37.5% (w/w) of the total mass of the micelle. PTX-loaded nanocarriers are much more stable than Abraxane® (PTX/human serum albumin nanoaggregate) when stored in bovine serum albumin solution or dog plasma. PTX release profile from the micelles is burst-free and sustained over a period of seven days. The anti-tumor activity of PTX-loaded nanocarriers against ovarian cancer cell line in vitro, with continuous drug exposure, is similar to Taxol® (formulation of PTX dissolved in Cremophor EL and ethanol) or Abraxane®. Targeted drug delivery to tumor site with these novel micelles was demonstrated by near infrared fluorescence (NIRF) imaging in nude mice bearing ovarian cancer xenograft. Furthermore, PTX-loaded nanocarriers demonstrated superior anti-tumor efficacy compared to Taxol® at equivalent PTX dose in ovarian cancer xenograft model.

show abstract

Section: Resultsmentioning

confidence: 50%

A novel size-tunable nanocarrier system for targeted anticancer drug delivery

Xiao

Luo

et al. 2010

Journal of Controlled Release

116

View full text Add to dashboard Cite

show abstract

“…The nanoparticles were prepared by the O/W emulsion solvent evaporation method (organic/aqueous ratio of 12% V/V) as previously reported. 24 Briefly, PLA was dissolved (3.3% w/V) in dichloromethane (DCM) in the case of PVP-PLA and cholate nanoparticles. When PEG-PLA was employed as emulsifier, PLA was dissolved in ethyl acetate in place of DCM.…”

Section: Methodsmentioning

confidence: 99%

Effect of Poly(N-vinyl-pyrrolidone)-block-poly(d,l-lactide) as Coating Agent on the Opsonization, Phagocytosis, and Pharmacokinetics of Biodegradable Nanoparticles

et al. 2009

Self Cite

View full text Add to dashboard Cite

The effect of the coating polymer poly(N-vinyl-pyrrolidone) (PVP) on the protein adsorption, phagocytosis, and pharmacokinetics of poly(D,L-lactide)-based nanoparticles was evaluated in vitro and in vivo. Control poly(ethylene glycol) (PEG)-coated nanoparticles were included for comparison. While no difference between PEG-and PVPdecorated nanoparticles in terms of amount of adsorbed protein was evident upon incubation in single protein solutions (BSA, IgG), incubation in serum revealed a protein adsorption pattern both quantitatively and qualitatively distinct. Larger amounts of complement components and immunoglobulins were found to adhere to PVP-coated particles, whereas PEG particles showed preferential adsorption of apolipoproteins. Furthermore, preopsonization in fresh rather than heat-inactivated serum enhanced uptake of both types of particles by murine RAW 264.7 macrophages. However, when isolated rat Kupffer cells were employed, activation of the complement system significantly enhanced the uptake of PVP-coated nanoparticles compared to PEG particles. Ultimately, PVPcoated nanoparticles exhibited considerably shorter circulation times compared to their PEG counterparts when administered intravenously to rats.

show abstract

“…In addition to PEG-modified PLGA micelles, PX-incorporated PVP-b-PLA micelles were prepared by Gaucher et al [50] by an o/w emulsion solvent evaporation method. The cryoprotectant property of PVP allowed the same particle size upon reconstitution after lyophilization, while PEG-modified PEG-b-PLA micelles did not.…”

Section: Poly(lactide) (Pla) Nanoparticlesmentioning

confidence: 99%

Paclitaxel Nano-Delivery Systems: A Comprehensive Review

Mumper²

2013

J Nanomedic Nanotechnol

421

240

View full text Add to dashboard Cite

Paclitaxel is one of the most effective chemotherapeutic drugs ever developed and is active against a broad range of cancers, such as lung, ovarian, and breast cancers. Due to its low water solubility, paclitaxel is formulated in a mixture of Cremophor EL and dehydrated ethanol (50:50, v/v) a combination known as Taxol. However, Taxol has some severe side effects related to Cremophor EL and ethanol. Therefore, there is an urgent need for the development of alternative Taxol formulations. The encapsulation of paclitaxel in biodegradable and non-toxic nano-delivery systems can protect the drug from degradation during circulation and in-turn protect the body from toxic side effects of the drug thereby lowering its toxicity, increasing its circulation half-life, exhibiting improved pharmacokinetic profiles, and demonstrating better patient compliance. Also, nanoparticle-based delivery systems can take advantage of the enhanced permeability and retention (EPR) effect for passive tumor targeting, therefore, they are promising carriers to improve the therapeutic index and decrease the side effects of paclitaxel. To date, paclitaxel albumin-bound nanoparticles (Abraxane®) have been approved by the FDA for the treatment of metastatic breast cancer and non-small cell lung cancer (NSCLC). In addition, there are a number of novel paclitaxel nanoparticle formulations in clinical trials. In this comprehensive review, several types of developed paclitaxel nano-delivery systems will be covered and discussed, such as polymeric nanoparticles, lipid-based formulations, polymer conjugates, inorganic nanoparticles, carbon nanotubes, nanocrystals, and cyclodextrin nanoparticles.

show abstract

Poly(N‐vinyl‐pyrrolidone)‐block‐poly(D,L‐lactide) as polymeric emulsifier for the preparation of biodegradable nanoparticles

Cited by 34 publications

References 44 publications

A novel size-tunable nanocarrier system for targeted anticancer drug delivery

A novel size-tunable nanocarrier system for targeted anticancer drug delivery

Effect of Poly(N-vinyl-pyrrolidone)-block-poly(d,l-lactide) as Coating Agent on the Opsonization, Phagocytosis, and Pharmacokinetics of Biodegradable Nanoparticles

Paclitaxel Nano-Delivery Systems: A Comprehensive Review

Contact Info

Product

Resources

About